https://adisinsight.springer.com/trials/700365533?error=cookies_not_supported&code=6ae25a77-689b-4c8c-bc2d-31d71d9fa3d2
Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic...
This is a single arm, multicentric phase II study of milademetan plus fulvestrant in patients with ER+, HER2- ABC harboring GATA3 mutation(s) in the tumor